FDA Expands Joenja Approval to Younger APDS Patients
PHAR is trading near its 52-week low of $9.62 (14% above the low).
Summary
Pharming received FDA approval to expand Joenja's label to a younger age group, broadening the addressable patient population for its key growth product. Joenja is already approved for APDS patients aged 12 and older; this expansion opens a new pediatric segment. The approval follows the recent EU marketing authorization and Japan launch, reinforcing Joenja's global commercial momentum. With Q2 revenue down 3% and RUCONEST declining, Joenja's expansion is critical to offsetting legacy product erosion. The company has not yet disclosed the specific age range or expected revenue impact.
At the time of this announcement, PHAR was trading at $11.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $759.5M. The 52-week trading range was $9.62 to $21.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.